Clinical trials: Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
The goal of this monocentric interventional study is to evaluate the efficacy, in terms of objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.
- Trial name
- Lip-Re2 (NCT05797870)
- Testing
- Selective Internal Radiation Therapy with 188Re-SSS lipiodol
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma
Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma
The objective is to evaluate the safety and therapeutic effect of combined hyperthermia and TACE for unresectable HCC
- Trial name
- NCT01817205
- Testing
- TACE with Hyperthermia Treatment
- Where
- 2 sites in Hong Kong
- Volunteers
- 8 people
- Sponsor
- Chinese University of Hong Kong
Liver Cancer
Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00039078
- Testing
- yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- Allan Tsung
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Although it is commonly accepted that antiviral therapy should be commenced before or during hepatocellular carcinoma (HCC) treatment if the patients have high viral loads and elevated ALT or total bilirubin values with signs of…
- Trial name
- NCT01894269
- Testing
- Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatocellulcar Carcinoma
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment…
- Trial name
- NCT07238881
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT06397222
- Testing
- Sin-Bev-SIRT
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX…
- Trial name
- NCT06904183
- Testing
- LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT05029973
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
The aim of this study is to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patients with unresectable…
- Trial name
- NCT04523467
- Testing
- Anti-angiogenic Targeted Drugs, Ginsenoside Rg3, TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Carcinoma, Hepatocellular
Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)
Most HCC patients are diagnosed at advanced stages in Korea, transcatheter arterial chemoembolization is considered a key modality for palliative treatment in these HCC patients.
- Trial name
- NCT00919009
- Testing
- TACE (Transcatheter Arterial Chemoembolization )
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery.
- Trial name
- NCT01835223
- Testing
- Tivozanib (1mg), Tivozanib (1.5mg)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Hepatocellular
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
The purpose of this study is to determine the maximal tolerated dose of idarubicin for chemoembolization of non resectable non metastatic hepatocellular carcinoma.
- Trial name
- NCT01040559
- Testing
- idarubicin
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hepatocellular Carcinoma (HCC)
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable…
- Trial name
- NCT07176650
- Testing
- HLX13, Yervoy, OPDIVO
- Where
- 51 sites in United States, China
- Volunteers
- 246 people
- Sponsor
- Shanghai Henlius Biotech
Liver Cancer
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
Brachytherapy is a recent technique used in the treatment of tumours and involves the use of radioactive sources brought into close contact with the target tissues.
- Trial name
- NCT00247260
- Testing
- 32P BioSilicon
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- pSiVida Limited
Hepatocellular Carcinoma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients
- Trial name
- NCT04368182
- Testing
- Autologous C-TCR055
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhejiang University
Hepatocellular Cancer, Cholangiocarcinoma
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects.
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
- Trial name
- NCT00465023
- Testing
- Proton Beam Radiation
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center